149 related articles for article (PubMed ID: 35107043)
1. Naltrexone at low doses (LDN) and its relevance to cancer therapy.
Liu WM; Dalgleish AG
Expert Rev Anticancer Ther; 2022 Mar; 22(3):269-274. PubMed ID: 35107043
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes.
Trofimovitch D; Baumrucker SJ
Am J Hosp Palliat Care; 2019 Oct; 36(10):907-912. PubMed ID: 30917675
[TBL] [Abstract][Full Text] [Related]
3. Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer.
Couto RD; Fernandes BJD
Curr Drug Res Rev; 2021; 13(2):86-89. PubMed ID: 33504322
[TBL] [Abstract][Full Text] [Related]
4. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.
Li Z; You Y; Griffin N; Feng J; Shan F
Int Immunopharmacol; 2018 Aug; 61():178-184. PubMed ID: 29885638
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy.
Qu N; Meng Y; Handley MK; Wang C; Shan F
Int Immunopharmacol; 2021 Jul; 96():107714. PubMed ID: 33989971
[TBL] [Abstract][Full Text] [Related]
6. Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy.
Liu WM; Scott KA; Dennis JL; Kaminska E; Levett AJ; Dalgleish AG
Int J Oncol; 2016 Aug; 49(2):793-802. PubMed ID: 27279602
[TBL] [Abstract][Full Text] [Related]
7. Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: a retrospective cohort study.
Martin SJ; McAnally HB; Okediji P; Rogosnitzky M
Pain Manag; 2022 Sep; 12(6):699-709. PubMed ID: 35289682
[TBL] [Abstract][Full Text] [Related]
8. Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.
Cabanas H; Muraki K; Eaton-Fitch N; Staines DR; Marshall-Gradisnik S
Front Immunol; 2021; 12():687806. PubMed ID: 34326841
[TBL] [Abstract][Full Text] [Related]
9. Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway.
Ma M; Wang X; Liu N; Shan F; Feng Y
Int Immunopharmacol; 2020 Jun; 83():106388. PubMed ID: 32171145
[TBL] [Abstract][Full Text] [Related]
10. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.
Younger J; Parkitny L; McLain D
Clin Rheumatol; 2014 Apr; 33(4):451-9. PubMed ID: 24526250
[TBL] [Abstract][Full Text] [Related]
11. Low-dose naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database.
Raknes G; Småbrekke L
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):685-693. PubMed ID: 28370746
[TBL] [Abstract][Full Text] [Related]
12. Functional modulation on macrophage by low dose naltrexone (LDN).
Yi Z; Guo S; Hu X; Wang X; Zhang X; Griffin N; Shan F
Int Immunopharmacol; 2016 Oct; 39():397-402. PubMed ID: 27561742
[TBL] [Abstract][Full Text] [Related]
13. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
14. Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin.
Metz MJ; Daimon CM; Hentges ST
eNeuro; 2021; 8(3):. PubMed ID: 34031099
[TBL] [Abstract][Full Text] [Related]
15. Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo.
Liu N; Ma M; Qu N; Wang R; Chen H; Hu F; Gao S; Shan F
Int Immunopharmacol; 2020 Sep; 86():106718. PubMed ID: 32585612
[TBL] [Abstract][Full Text] [Related]
16. Low dose naltrexone for induction of remission in Crohn's disease.
Segal D; Macdonald JK; Chande N
Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.
Toljan K; Vrooman B
Med Sci (Basel); 2018 Sep; 6(4):. PubMed ID: 30248938
[TBL] [Abstract][Full Text] [Related]
18. The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response.
Aboalsoud A; El-Ghaiesh SH; Abd Elmonem FF; Salem ML; Abdel Rahman MN
Int Immunopharmacol; 2020 Jan; 78():106068. PubMed ID: 31835085
[TBL] [Abstract][Full Text] [Related]
19. Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs).
Meng J; Meng Y; Plotnikoff NP; Youkilis G; Griffin N; Shan F
Int Immunopharmacol; 2013 Dec; 17(4):1084-9. PubMed ID: 24455776
[TBL] [Abstract][Full Text] [Related]
20. Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis.
Zagon IS; Rahn KA; Turel AP; McLaughlin PJ
Exp Biol Med (Maywood); 2009 Nov; 234(11):1383-92. PubMed ID: 19855075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
